ArticleBritish journal of cancer1996
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
Article in British journal of cancer, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.Cancer research communications · 2026Trial
- Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.British journal of cancer · 2004Trial
- Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us.International journal of molecular sciences · 2023Review
- Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Drug Resistance of CPT-11 in Human DLD-1 Colorectal Cancer Cells through MutS Homolog 2 Upregulation.International journal of medical sciences · 2021Article
- Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.BMC cancer · 2019Article
- Gold nanoparticles - an optical biosensor for RNA quantification for cancer and neurologic disorders diagnosis.International journal of nanomedicine · 2018Article
- Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.BMC cancer · 2017Article
- Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.Journal of experimental & clinical cancer research : CR · 2016Article
- Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.BMC cancer · 2016Article
- Pharmacologic resistance in colorectal cancer: a review.Therapeutic advances in medical oncology · 2016Review
- Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.World journal of gastroenterology · 2014Review
- Topoisomerase I as a biomarker: detection of activity at the single molecule level.Sensors (Basel, Switzerland) · 2014Article
- Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.Surgery today · 2011Review
- First-line treatment strategies to improve survival in patients with advanced colorectal cancer.Drugs · 2004Review
- DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?Pathology oncology research : POR · 1999Review
- Identification of genetic changes associated with drug resistance by reverse in situ hybridization.British journal of cancer · 1997Article
- Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization.Neoplasia (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA topoisomerase I (topo I) is the principle target for camptothecin and its derivatives such as SN38. Levels of topo I expression vary widely between and within tumour types and the basis for this is poorly understood. We have used fluorescence in situ hybridisation to detect the topo I locus in a panel of breast and colon cancer cell lines. This approach has identified a range of topo I gene copies from 1 to 6 between the cell lines as a result of DNA amplification, polysomy and isochromosome formation. Topo I gene copy number was highly correlated with topo I expression, (rs = 0.92), and inversely correlated to sensitivity to a 1 h exposure to SN38 (rs = -0.904). This illustrates the significant impact of altered topo I gene copy number on intrinsic drug sensitivity and influences potential mechanisms for acquisition of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.